U.K. Entertainment Stock News

How Shell’s recent performance sets the stage for investors Shell (LSE:SHEL) has been on many investors’ radar after a period where the share price showed a mix of short term softness, with a 1 day return of around a 1% decline, and stronger gains over the past month and the past 3 months. See our latest analysis for Shell. With the share price at £31.13, Shell’s recent 1 month share price return of 11.42% and year to date gain of 12.81% contrast with a much stronger 5 year total shareholder...

Fresnillo (LSE:FRES) reported record financial performance for the year, with revenues and profits at all time highs. The company achieved this result despite declines in silver and gold production. Fresnillo also paid its highest dividend since its listing, supported by elevated precious metal prices. Fresnillo is a major precious metals producer, with a core focus on silver and gold. The latest results come at a time when precious metal prices have been elevated, which can have a strong...

HSBC Holdings (LSE:HSBA) has named Dame Carolyn Fairbairn as the next chair of HSBC UK, succeeding the current incumbent after regulatory approvals. The group is also progressing with the sale of its Indonesian consumer banking operations, with several Southeast Asian banks reported to be interested in the assets. These moves come as HSBC continues to refine its global footprint and governance structure across key markets. For investors watching HSBC Holdings at a current share price of...

Recent performance snapshot for BP (LSE:BP.) With no single headline event driving attention, BP (LSE:BP.) has still attracted interest after a period where the shares show a one-month return of 6.30% and a three-month return of 6.25%. See our latest analysis for BP. At a share price of £4.93, BP’s recent share price momentum, with a 7 day share price return of 4.63% and year to date share price return of 12.58%, sits alongside a 1 year total shareholder return of 27.94% and 5 year total...

Diageo (LSE:DGE) has closed its Crown Royal whisky plant in Amherstburg, Ontario, resulting in over 200 job losses with limited notice to staff. Production for Crown Royal is shifting to facilities in the US following the Amherstburg shutdown. The company has cut its interim dividend by around half after reporting disappointing results. Diageo is facing pressure in agave spirits, with weaker sales and a lawsuit challenging the authenticity of Casamigos and Don Julio. Diageo (LSE:DGE) sits...

Rio Tinto has approved the resumption of the Zulti South mineral sands project in South Africa, including a $473m investment. The company is also progressing work on primary gallium extraction in Quebec, supported by research partners and the Canadian government. Both projects are aimed at securing long term supplies of materials used in industrial applications and emerging technologies. Rio Tinto Group (LSE:RIO), trading at around £73.36, sits in the large cap mining space with returns of...

Glencore at a glance: share performance and recent momentum Glencore (LSE:GLEN) has attracted fresh attention after a strong run in recent months, with the share price posting a 7.0% return over the past month and 48.3% over the past 3 months. Over longer periods, the stock shows a 30.7% year to date return and a 69.9% total return over the past year. The 5 year total return stands at 134.1%, suggesting meaningful long term compounding for investors who stayed invested. The company reports...

BAE Systems (LSE:BA) has launched Silver Link™, a new modular antenna portfolio for airborne communications. The company secured a major US Army contract for advanced self-propelled howitzers. BAE Systems reached a production milestone with delivery of its 100,000th APKWS laser guided kit. For investors watching large defense contractors, these three updates give a clearer view of how BAE Systems earns its place in modern military programs. The company is active across precision munitions,...

Barclays (LSE:BARC) is facing potential financial and reputational impact after the collapse of Market Financial Solutions, a specialist mortgage lender. The bank had significant exposure to MFS and identified suspicious activity early, freezing accounts and blocking related transactions ahead of the lender's insolvency. Fraud and irregularity allegations at MFS are prompting fresh scrutiny of underwriting standards and controls in leveraged lending structures and private credit...

If you are wondering whether Shell’s current share price gives you good value or not, you are in the right place to unpack what the market might be pricing in. Shell’s shares last closed at £31.32, with returns of 5.6% over 7 days, 12.1% over 30 days, 13.5% year to date, 22.6% over 1 year and 35.9% over 3 years. This gives you a useful backdrop before comparing the price to underlying value. Recent headlines around Shell have focused on its position in the global energy sector and how...

Wondering if AstraZeneca's current share price reflects its true worth, or if the market is getting ahead of itself? This article is built to help you make sense of the valuation. With the share price at £152.52 and returns of 12.1% over 30 days, 12.2% year to date and 30.4% over 1 year, AstraZeneca has recently seen meaningful moves that can change how investors view its potential and risk. Recent news coverage has focused on AstraZeneca's product pipeline, partnerships and regulatory...

How NatWest Group’s Recent Performance Frames the Investment Question NatWest Group (LSE:NWG) has seen mixed share performance recently, with a 1 day decline and a small gain over the past week, while returns over the month and past 3 months have been negative. At the same time, the bank reports annual revenue of £15,970.0m and net income of £5,479.0m, alongside positive annual revenue and net income growth rates. This gives investors concrete numbers to weigh against recent share price...

GSK (LSE:GSK) is acquiring Canadian biotech 35Pharma in a deal valued at nearly US$1b. The transaction brings 35Pharma’s investigational activin signaling inhibitor HS235 into GSK’s pipeline. HS235 is being developed for pulmonary arterial hypertension and related cardiopulmonary conditions. For GSK, known for its focus on respiratory and specialty medicines, the 35Pharma deal adds another late stage cardiopulmonary asset alongside its existing portfolio. Pulmonary arterial hypertension...

If you are wondering whether Barclays shares still offer value after a strong run, this article will walk through what the current price really implies. The stock has pulled back recently, with a 4.4% decline over the last 7 days and a 5.6% decline over the last month, although the 1 year return sits at 48.4% and the 3 year return at 192.2%. Alongside these recent moves, Barclays has remained in focus for long term investors who are reassessing banks in light of changing interest rate...

If you are wondering whether Fresnillo’s recent share price strength still leaves any value on the table, or if you might be late to the story, this article walks you through what the current market price could be implying. Fresnillo’s shares last closed at £42.40, with returns of 10.0% over the past week, 8.7% over the past month, 26.5% year to date and a very large gain over the past year and past five years based on the data provided. Those moves sit against a backdrop of ongoing interest...

If you are wondering whether Rolls-Royce Holdings is still good value after its run up, this article will walk you through what the current price might be implying about the stock. The share price has been volatile recently, with a 0.2% decline over the last 7 days, a 10.4% gain over the last 30 days, an 11.4% return year to date, an 81.5% return over 1 year, and a very large 3 year and 5 year return that is well above 7x. Recent coverage around Rolls-Royce has focused on its position as a...

If you are wondering whether Lloyds Banking Group shares still offer value after their recent run, this article will walk through what the current price might be implying about the stock. The share price recently closed at £1.0245, with returns of 3.2% year to date and 47.4% over the past year, alongside shorter term moves of a 1.6% decline over 7 days and a 2.0% decline over 30 days. These changes can shift how investors think about both upside and risk. Recent news coverage has focused on...

Rolls-Royce Holdings announced a multi-year share buyback programme of up to £9b. The company sharply raised its mid term financial targets alongside the buyback plan. Rolls-Royce is seeking substantial UK government support for new narrow body aircraft engines and small modular reactors. For investors watching Rolls-Royce Holdings (LSE:RR.), these moves come after a very large three-year share price gain and a current price of £13.335. The stock is up 11.4% year to date and 81.5% over the...

Lloyds Banking Group (LSE:LLOY) is back in focus for investors after recent share price moves, with the stock showing different return patterns over the past week, month and past 3 months. See our latest analysis for Lloyds Banking Group. At a share price of £1.049, Lloyds Banking Group has seen short term share price momentum cool compared to its recent 90 day share price return of 9.11%. At the same time, the 1 year total shareholder return of 53.60% and 3 year total shareholder return of...

Shell and METLEN have signed an LNG supply and trading agreement tied to the Vertical Gas Corridor, aimed at improving regional gas flows in Europe. Shell has begun arbitration proceedings with Kazakhstan related to environmental fines at the Kashagan oilfield. These moves come as investors watch how Shell balances European gas growth with legal and environmental disputes. LSE:SHEL is trading at £30.24, with the share price up 12.1% over the past month and 9.6% year to date. Over the past...

If you are wondering whether BP's current share price really reflects its underlying value, you are not alone. This article will walk through what the numbers actually say. Over the short term, BP's share price shows a 1% decline over the last 7 days, a 4.9% return over 30 days, 8.3% year to date, 14.7% over 1 year and 94.3% over 5 years. This performance may lead investors to reassess both its growth potential and its risk profile. Recent headlines around BP have focused on its role as a...

FDA approval granted for a new CALQUENCE combination therapy in chronic lymphocytic leukemia. Positive Phase III results reported for BREZTRI in patients with uncontrolled asthma. EMA validates a filing for ENHERTU in HER2 positive breast cancer. AstraZeneca, LSE:AZN, is adding fresh clinical and regulatory progress to a share price that stands at £151.1. The stock has returned 11.2% year to date and 27.9% over the past year, with a 47.7% return over three years and 144.9% over five years...

Context for GSK after recent share moves GSK (LSE:GSK) has recently drawn attention after a mix of short term share price weakness and stronger longer term returns, prompting investors to reassess how its current valuation lines up with recent business performance. See our latest analysis for GSK. The recent 2.1% one day and 2.7% 7 day share price declines contrast with GSK's 16.4% 1 month and 18.3% year to date share price returns, alongside a 54.4% 1 year total shareholder return. This...

Why Fresnillo (LSE:FRES) is on investors’ radar today Fresnillo (LSE:FRES) has attracted attention after a mixed pattern in recent share returns, including a roughly 5% decline over the past day alongside a gain of about 56% in the past 3 months. See our latest analysis for Fresnillo. At a share price of £41.04, Fresnillo’s recent 6% 7 day share price return sits alongside a roughly 56% 90 day share price return and a very large 1 year total shareholder return. Taken together, these figures...